Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical studyACI-35.030 is a clinical stage […]
Summit Therapeutics plc (‘Summit’ or the ‘Company’)Summit Announces Intention to Redomicile its Holding Company to the United StatesOxford, UK, and Cambridge, […]